Human cytochrome P450 2B6 ( CYP2B6 ) metabolizes the prodrug cyclophosphamide ( CPA ) to produce phosphoramide mustard that cross -links DNA leading to cell death. We have constructed a novel retroviral vector encoding CYP2B6 ( designated``MetXia -P450'' ) and used it to transduce the human tumor cell lines HT29 and T47D. MetXia -P450 transduction sensitised these cells to the cytotoxic effects of the prodrug CPA. Results from in vitro experiments demonstrated adverse effects on the clonogenic survival of cyclophosphamide -treated cells transduced with MetXia -P450. Cytotoxic activity accompanied by bystander effect was particularly evident in 3 -D multicellular spheroid models suggesting that this in vitro system may be a more appropriate model for assessing the efficacy of gene directed -enzyme prodrug therapy ( GDEPT ). We have applied this approach in a clinically relevant gene therapy protocol on established subcutaneous tumor xenografts. These studies show for the first time the efficacy of a P450 -based GDEPT strategy mediated by a direct retroviral gene transfer in vivo. Cancer Gene Therapy ( 2001 ) 8, 473 ± 482
G ene -directed enzyme prodrug therapy (GDEPT ) involves the delivery of a gene encoding a prodrugactivating enzyme, which metabolizes a nontoxic prodrug to produce a toxic metabolite. In most cases this toxic metabolite is freely diffusible and is able to kill neighbouring cells, termed the``bystander effect. '' GDEPT strategies include the use of viral, bacterial, or mammalian enzymes to activate prodrugs. 1 In many cases the activated compounds are nucleotide analogues, e.g., ganciclovir /thymidine kinase ( GCV /TK ) that work by disrupting DNA synthesis. 2, 3 In other strategies the activated compound damages DNA directly via DNA alkylation, for example, nitroreductase activation of the prodrug CB1954 4, 5 and cytochrome P450 activation of cyclophosphamide (CPA). 6 ± 11 Also, these systems can effectively target both actively dividing and nondividing tumor cells.
The principle behind GDEPT is to exploit a metabolic conversion that would not normally occur to any significant level in human cells. This might suggest that using nonmammalian enzymes would be preferred. In the TK strategy, there is no analogous activity in human cells; however, this advantage is offset by the gap junction ± limited bystander effect in the GCV /TK system. In the case of nitroreductase, normal mammalian tissues express DT diaphorase, which has a certain level of activity against the prodrug substrate CB1954. Specificity is, therefore, not absolute with these nonmammalian enzymes. Furthermore, as they are foreign, an immune response may be elicited that will impact on the ability to perform repeat dosing.
To overcome some of these limitations, GDEPT approaches have been established that use cytochrome P450 enzymes to activate the conventional chemotherapeutic CPA. These enzymes are primarily expressed in the liver and, therefore, active metabolites have to travel to a tumor site that is often distal to the site of activation. To achieve significant killing of tumor cells it is necessary to use high doses of CPA that often results in neurotoxicity, cardiotoxicity, urotoxicity, and bone marrow suppression. GDEPT provides the opportunity for local prodrug activation at the target site, thereby improving the therapeutic index and safety of CPA treatment.
Early studies using the rat P450 2B1 gene showed that stable cell lines were made sensitive to CPA. 12 More recently, efficacy has been obtained with in vitro selected glioma cells transduced with cytochrome P450 2B6 ( CYP2B6 ) via a retroviral vector. 9 To date, however, there have been no studies reported of the effectiveness of this approach in an in vivo gene -delivery model where a retroviral vector is injected directly into an established tumor.
In our P450-based GDEPT approach, we have selected the human homologue, CYP2B6, to avoid any potential immune response that could prejudice therapy and have evaluated the therapeutic potential of P450 in the context of a retroviral vector (designated MetXia -P450). We have extended the analysis of the effectiveness of this strategy in vitro using a 3-D spheroid model that appears to mimic more closely the in vivo situation than monolayer cultures. We have then shown a significant effect of a combined treatment with the MetXia-P450 vector and CPA on tumor growth after direct in vivo administration. These data suggest that in vivo gene therapy using vectors expressing cytochrome P450 may be useful in the treatment of breast and colon cancer.
MATERIALS AND METHODS

Cell lines
Unless stated otherwise cells were purchased from European Collection of Cell Cultures ( ECACC, Salisbury, UK ) and culture media were purchased from Sigma, Poole, UK. 293T ( Stanford University 13 ) cells were cultured and maintained in EMEM. TEFLYA ( Genethon, Paris, France ), HT29, MDA -MB231, and D17 cells were cultured in DMEM and T47D cells were cultured in RPMI -1640 medium. All media were supplemented with 10% (vol / vol ) fetal calf serum, 2 mM L -glutamine and 1X nonessential amino acids. For cytotoxicity assays and spheroid assays, culture media were additionally supplemented with 50 U /mL penicillin and 50 g/ mL streptomycin.
bps
Construction of a retroviral vector expressing CYP2B6 ( MetXia -P450 )
CYP2B6 cDNA was obtained from total human liver RNA ( Clontech, Palo Alto, CA ) via standard RT-PCR and was then amplified using the forward primer``P450for'' ( sequence: tcatgctagc ggatccacca tggaactcag cgtc ) and complement primer``P450rev'' ( sequence: aaaatcacac tctagattcc ctcagcccct tcagc ). The PCR product was subsequently cloned into the pCRII-TOPO TA cloning vector ( Invitrogen, Paisley, UK ) and the final construct was designated OBM 27. Coding sequence of CYP2B6 in OBM27 corresponded to that in Genbank (accession number M29874 ) except for a single silent change at nucleotide 1182 ( T to C ) relative to the ATG starting codon.
To express CYP2B6 in a retroviral vector, we have constructed an MLV-based retroviral vector, MetXia, with an internal ribosome entry site (IRES ) from encephalomyocarditis virus (EMCV ) to coexpress CYP2B6 and nlsLacZ The EMCV IRES element was amplified from the pIRES-hyg vector (Clontech ) adding a NotI site to the 5 H end and an NcoI site spanning the original IRES initiating ATG codon (forward primer: catgcatcta GGGCGGCCG Cactagag, reverse: ggttgtggcC CATGGtatca tcgtgttttt caaagg). Reporter gene nlsLacZ was amplified from the pHIT111 plasmid vector 14 using forward primer (sequence: ctcagcaccc tcgagaggcc tgccaccatg gggactgctc caaagaagaa gcgtaaggta gtcgttttac aacgtcgtga c) and reverse primer (sequence: gatcggtgcg ggcctcttcg ) to incorporate the SV40 large T antigen nuclear localisation signal 15 PKKKRKV to the lacZ gene. MetXia consists of a backbone from the pLXSN plasmid vector 16 ( Genbank accession number 28248 ). The 5 H -LTR of LXSN was replaced with the 5 H -LTR fragment from the pHIT111 plasmid, 22 which contains a CMV promoter element in the U3 region. A gene cassette containing a``kozak'' optimised CYP2B6 coding sequence (see above paragraph ), an EMCV IRES and nlsLacZ was inserted before the SV40neo selection marker gene cassette ( Fig 1) . The final construct was designated as MetXia-P450.
Production of MetXia -P450 retroviral vector
Transient production of MetXia -P450 retroviral vector was performed using a three -plasmid expression system as previously described 14 with some modifications. Briefly, a mixture of DNA plasmids containing the genome CYP2B6, MLV gag -pol, and the vesicular somatitis virus G glycoprotein ( VSV-G ) at a ratio of 2:2:1 was used to cotransfect 293T cells. MetXia-P450 retroviral particles were harvested and filtered through a 0.45-m filter. Viral titre was determined using D17 cells and standard X -gal staining.
Transiently produced MetXia -P450 pseudotyped with VSV-G was used to transduce a population of TEFLYA packaging cells (Genethon ). MetXia -P450 producing clones were then selected by growing in culture medium containing 1 mg /mL Geneticin and screened for high lacZ expression.
Establishment of HT29 / MetXia -P450 and T47D / MetXia -P450 cells HT29 or T47D ( 1Â10 5 ) cells were transduced with MetXia-P450 at an MOI of 7.5 in complete medium containing 8 g/ mL polybrene (Sigma). These cells, designated as HT29 / MetXia -P450 or T47D /MetXia -P450 cells, were selected with 1 mg /mL Geneticin for 2 ± 3 weeks and the percentage of transduced cells was scored as lacZ expressing cells using standard X -gal staining.
Microsome preparation and detection of CYP2B6 protein by Western blotting
Cells at a density of 2Â10 7 /mL were suspended in Nuclear buffer (10 mM Hepes/ KOH, pH 7.4 containing 1.5 mM MgCl 2 , 10 mM KCl, and 0.05 mM DTT ) and were then sonicated with a microtip sonicator probe (Misonix XL2015, Farmingdale, USA ) for 4Â5 seconds (30 seconds icecooling in between ) with pulse cycle output at 40% and output power setting at 5. The sonicate was centrifuged at 7800Âg, 48C for 15 minutes to remove debris. Microsome pellet was later obtained through centrifugation at 100,000Âg, 48C for 45 minutes using a Beckman Optima XL -100 ultracentrifuge.
Expression of CYP2B6 protein was later detected by standard Western blotting technique. Microsome protein samples ( 30 g ) were lysed in standard Laemmli's buffer and loaded onto a 10% Tris ±glycine polyacrylamide gel ( Invitrogen ). Blotting was performed with the X -Cell II Mini -cell system (Invitrogen ). A primary polyclonal rabbit antibody against CYP2B6 ( GENTEST, Woburn, MA, 1:2000 dilution ) and a secondary peroxidase conjugated goat anti -rabbit anti -serum ( Dako, Ely, UK, 1:2000 dilution ) were used to immunostain the membrane. The membrane was developed in ECL reagents (Amersham KAN, GRIFFITHS, BABAN, ET AL: P450 GDEPT BY DIRECT RETROVIRAL GENE DELIVERY Pharmacia Biotech, Piscataway, NJ ) and then exposed on Hyperfilm -ECL (Amersham Pharmacia Biotech).
Measurement of changes in clonogenic survival of cells by colony -forming assay
Cells treated with CPA for 7 days were then plated out at a cell density of 2000, 200, and 20 cells in six -well plates in duplicates and were incubated at 378C in a CO 2 incubator for 2 weeks to allow colony formation. Cells were stained with 1% ( wt/ vol ) of crystal violet (Sigma) in 4% formal saline ( BDH, Lutterworth, UK ). Colonies consisting of 50 cells or more were scored.
Construction of tumor spheroids and relevant histological studies
Ninety -six ±well plates (Falcon, Stratech, Luton, UK ) were coated with a 22 mg / mL agarose solution containing 10% ( vol /vol ) 10Â EMEM, 5% (vol / vol ) 7.5% NaHCO 3 L DMEM supplemented with 10% ( vol /vol ) fetal calf serum, 2 mM L -glutamine and 50 U/ml penicillin and 50g/ ml streptomycin. Spheroids formed after 14 days were used for experiments.
Using standard histochemical techniques, paraffin wax ± embedded spheroids were sectioned and stained with haematoxylin and eosin (Sigma). Sections were also stained for apoptotic /necrotic cells using the TUNEL POD kit ( Roche, Lewes, UK ).
For evaluating the effect of CPA on T47D / MetXia-P450 ± transduced cells containing spheroids, T47D and T47D /MetXia-P450 cells were mixed in the appropriate ratio before seeding into 96-well plates. At day 7 after seeding, the spheroids were treated with CPA ( 0.5 mM ) for a further 7 days and photographed before fixing in 4% histological grade formal saline ( BDH ) for 24 hours for subsequent histological studies.
Assessment of the efficacy of MetXia -P450 in vivo
All the animal experiments were carried out under the standard UK Home Office guidelines. For safety and toxicity studies, 100 -l dose of MetXia -P450 retroviral vector was administered by two routes (intravenously or intraperitoneally ) into non ±tumor-bearing athymic nude mice ( female Balb /c nu/ nu, Harlan, Bicester, UK ). These mice were carefully monitored up to 14 days for signs of adverse reaction. At the end of the study, the organs of these mice were examined for damage, signs of disease, or pathological lesions.
Tumor growth studies were conducted in nude mice using HT29 (human colon carcinoma ), MDA -MB231 ( human breast carcinoma ), and MDA -MB468 (human breast carcinoma ) xenografts. HT29 ( 3Â10 6 cells /100 l DMEM ) cells were implanted subcutaneously. MDA -MB231 or MDA -MB468 cells were implanted at 5Â10 KAN, GRIFFITHS, BABAN, ET AL: P450 GDEPT BY DIRECT RETROVIRAL GENE DELIVERY cells/100 l DMEM made up with 30% Matrigel (Stratech, Luton, UK ). Tumor cells were implanted at two flanks per mouse and allowed to develop to an average diameter of 5 mm before start of the protocol. Starting from day 1, five daily 100-l doses of approximately 5Â10 5 lacZ colonyforming units of MetXia -P450 were administered by direct intratumoral injection. Starting from day 6, two daily 100-l doses of 150 mg /kg CPA were administered intraperitoneally to each animal. Groups were partitioned for the assessment of biodistribution, toxicity, efficacy of gene transfer, and response to CPA treatment. Throughout the study the health of the mice were carefully monitored up to 21 days after commencing intratumoral administration of MetXia -P450.
To assess the efficacy of gene transfer, excised tumor samples were fixed in 4% formal saline (BDH ) and processed to wax embedding. Sections were then stained with an anti -lacZ antibody and developed using 3,3
Hdiaminobenzidine (DAB, Sigma ). Tumor growth was monitored using caliper measurements. Two measurements for each tumor (two per mouse ) were taken at daily intervals throughout the study. Mean tumor volume of individual tumors were calculated using the formula /6(d 1 d 2 )
3 / 2 where d =diameter. Daily changes in mean tumor volumes were plotted according to group. Tumor growth in treated and control mice was compared using the nonparametric one -way Kruskal -Wallis analysis of variance (ANOVA ). HT29 /MetXia-P450 and T47D /MetXia-P450 were found to be 85% and 90%, respectively. CYP2B6 protein was clearly expressed in HT29 /MetXia -P450 and T47D / MetXia -P450 cells (2.29 pmol /mg microsomal protein, assessed by quantitative Western blot ) and not in the corresponding parental cells ( Fig 2 ) . In addition, the expression of CYP2B6 protein was shown in 293Pcl11, i.e., 293 cells stably transfected with cyp2B6 and JS9 ( a MetXia -P450 producing FLYA13 clone ) cells but not in the parental FLYA13 retroviral packaging cells.
RESULTS
Expression
17
MetXia -P450 sensitises tumor cells to CPA toxicity through the inhibition of their clonogenic survival A colony -forming assay was performed to investigate the longer term damage of CPA on the growth and clonogenic survival of MetXia -P450 ± transduced cells. Colony formation was reduced by more than 95% in HT29 /MetXia-P450 cells treated with 0.5 mM CPA. Similarly in the case of T47D /MetXia -P450 cells, clonogenic survival was reduced by at least 85%. No reduction in the clonogenic survival of parental HT29 or T47D cells was observed ( Fig 3 ) .
Efficacy of MetXia -P450 and CPA in a 3 -D tumor spheroid culture system
To examine the effects of CPA in a 3-D culture system, tumor spheroids were grown from differing proportions of stable MetXia -P450 ± transduced and untransduced T47D cells. As tumor spheroids grow in diameter, nutrients become diffusion limited causing the death of cells in the center of KAN, GRIFFITHS, BABAN, ET AL: P450 GDEPT BY DIRECT RETROVIRAL GENE DELIVERY the spheroid and the formation of a necrotic core. However, a viable rim of tumor cells remains and continues to grow. 18 After treatment with CPA, spheroids containing T47D / MetXia -P450 cells had a smaller volume than their untreated controls ( Fig 4 ) . The necrotic core in the CPA -treated tumor spheroids containing T47D /MetXia-P450 cells was either smaller or absent. It is possible that their growth was delayed by the CPA treatment, and therefore the cells at the center were not diffusion limited for nutrients. Analysis of the histological sections and TUNEL staining (Fig 5 ) for DNA strand breakages revealed that CPA -treated MetXia -P450 ± transduced tumor spheroids also had considerable necrosis in the viable rim. This was not the case in the controls, which clearly displayed necrotic cores.
Enhancement in CPA -mediated inhibition of clonogenic survival in unselected,``freshly'' MetXia -P450 ± transduced tumor cell lines
As presented in Figure 3 , CYP2B6 /CPA GDEPT showed efficacy on selected stable transductants HT29 / MetXia-P450 and T47D /MetXia -P450 cells. To see whether similar results could be obtained with unselected, freshly transduced tumor cells, we have employed the same assay to assess CPA -mediated inhibition of clonogenic survival in unselected tumor cells exposed to MetXia -P450 vector. HT29 and T47D cells freshly transduced with the MetXia -P450 retrovirus were clearly sensitised to the cytotoxic effect of CPA ( Fig 6) . Our results showed a reduction of more than 60% of colonies formed by cells exposed to MetXia -P450 followed by CPA ( Fig 6 ) . The percentage of cells expressing lacZ ( as an indication of CYP2B6 expression ) in the HT29 and T47D populations was found to be 4.6% and 6.7%, respectively.
MetXia -P450 and CPA induced tumor growth delay in mice harboring subcutaneous human tumor xenografts Safety and toxicity studies ( see Materials and Methods for details ) showed no adverse reactions during or after MetXia -P450 administration. At the end of the study, all animal organs were examined and showed no signs of defect, disease or pathological lesions (data not shown ).
Results from two independent tumor growth experiments using HT29 cells showed that mice treated with MetXia -P450 and CPA had a significant delay in tumor growth (Fig 7 ) when compared with those treated with MetXia -P450 alone ( P <.001 ), treated with CPA alone ( P <.001 ), or untreated control mice ( P <.04 ). Similar results were obtained using the MDA -MB -231 breast carcinoma cells. MetXia -P450 and CPA caused a significant tumor growth delay when compared with the following control groups, MetXia-P450 alone (P < .001 ), CPA alone (P < .001 ) or untreated mice (P < .02) ( Fig 8 ) . Some of the tumors in these animals were harvested for a colony -forming assay. Control tumor cells formed 10 times more colonies than tumor cells exposed to MetXia-P450 and CPA ( data not shown ). Gene transfer of MetXia -P450 to subcutaneous human tumor xenografts was assessed by histological staining for lacZ expression.
Results from stained sections, by lacZ immunohistochemistry and X -gal staining, of tumors exposed to MetXia-P450 retroviral vector indicated that less than 5% tumor cells were expressing lacZ ( data not shown). The expression of P450 and lacZ in MetXia-P450 ±transduced tumor cells were examined by immunohistochemistry and X -gal staining and found to be expressed in a similar pattern ( data not shown ). This suggested a significant bystander cell killing in tumors under the action of CYP2B6 and CPA.
DISCUSSION
In the present study we have evaluated the therapeutic potential of CYP2B6 in a preclinical gene therapy setting, with prior consideration of using a human enzyme to avoid undesirable immune reactions in patients. A direct retroviral vector delivery strategy was used in preference to implantation of retroviral producer cell clones on the basis of safety. Even though some researchers 10, 19 have developed an encapsulation method to deliver CYP2B1-expressing cells to bypass the host immune reaction, the secretion of unknown proteins by these cells or possible escape of these cells from the capsule may raise safety concerns.
Our study showed that CYP2B6 protein was successfully expressed in HT29 and T47D cells transduced with MetXia -P450. The ability of the introduced CYP2B6 to metabolize CPA leading to cell damage in these cells was also investigated. Our data agree with those described by other researchers using the rat homologue CYP2B1 transfectants 6, 8, 11, 12, 20, 21 and P450 human isoforms. 9 As predicted, colony formation by HT29 or T47D cells was unaffected by CPA treatment. However, when MetXia-P450± transduced HT29 or T47D cells were treated with the same dose of CPA, there was a profound decline in clonogenic survival. Even if some cells were still slowly recovering from the cytostatic effect of CPA, a range of smaller colony sizes should have been observed. However, these small colonies were rarely seen in our experiments. A bystander cell killing effect was also reflected in our experiments performed on freshly transduced, CPA -treated tumor cell populations. Even though only a minor population (less than 7% ) of the cells express detectable CYP2B6, CPA treatment caused a profound decrease (over 60% ) in clonogenic survival of these cells. Nevertheless, monolayer culture studies may not be optimal as the shortlived metabolite 4 -OH -CPA is readily diffused into the medium overlaying the cells resulting in a massive dilution. Thus, any bystander killing effect may well be underrepresented in these assays. To mimic the situation in vivo, we have constructed a tumor spheroid model where cells are in 3-D contact with each other. Using this multicellular model we have observed some major changes in the appearance and infrastructure in spheroids containing T47D /MetXia -P450 cells when they were treated with CPA. The changes include a moderate reduction in size and an increase in necrotic space in the viable rim of the spheroid. In addition, more apoptotic /necrotic cells were present in CPA -treated spheroids containing T47D /Met-Xia -P450 cells by TUNEL immunostaining than in the CPA -treated parental cells.
Furthermore, the concept of using CYP2B6 /CPA in a clinically acceptable GDEPT strategy is strongly supported by the results from in vivo experiments using nude mice with subcutaneous tumor xenografts. When the tumor growth in animals was monitored, only mice receiving both MetXia-P450 injection and CPA show a delay in tumor growth, beginning 6 ±7 days after CPA was administered. This growth delay clearly stands out from the controls at day 21. MetXia -P450 itself was found to be nontoxic to these animals and did not cause any physical or pathological damage to their internal organs.
Our results have confirmed the efficacy of the P450 /CPA prodrug GDEPT strategy demonstrating that both MetXia-P450 and CPA are required to elicit a tumor growth delay. The extent of this growth delay seen with the MetXia -P450 /CPA is perhaps surprising in the light of the modest levels of gene transfer detected in these experiments. Because our in vitro data from monolayer cultures have already suggested a significant bystander cell killing effect, which appeared more pronounced in the 3 -D tumor spheroids, the reduction in tumor mass in vivo may confirm this observation. In summary, we have demonstrated a clear antitumoral response by growth delay in vivo using CYP2B6 /CPA GDEPT.
Our CYP2B6 /CPA GDEPT approach for cancer gene therapy has many advantages. CYP2B6 is a nontoxic human gene and the pharmacokinetics of the prodrug CPA is well characterised. The complete lack of toxicity to MetXia -P450 from our data underlines the safety of this approach. Moreover, delivery of phosphoramide mustard to tumors exposed to MetXia -P450 can be augmented by endogenous enzyme activation of CPA in the liver. Also, the therapy could be terminated by merely withdrawing CPA if there is any sign of an adverse reaction. Furthermore, this approach may be more effective in immunocompetent animals, as previously pointed out by Chong and coworkers. 22, 23 Clearly, gene transfer using a retroviral vector is sufficient to create a depot of enzymes capable of significant bystander killing. MetXia -P450 holds promise as a gene therapy vector for a range of solid tumors and is currently in clinical development for the treatment of advanced breast and ovarian cancer.
